Physician profile
Richards A Afonja
NPI 1255300141
$9,218.62
in general payments reported to CMS, 2019-2025
56 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,721 · 2020: $392 · 2021: $1,308 · 2022: $1,015 · 2023: $1,175 · 2024: $1,573 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,383 · Education: $232 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,382.69 |
| Education | $232.39 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,957.68 | 2019-2025 | |
| Janssen Biotech, INC. | $898.06 | 2019-2025 | Darzalex, Tecvayli, Erleada |
| Astrazeneca Pharmaceuticals LP | $883.43 | 2019-2025 | Farxiga, Lynparza, Breztri |
| Pfizer INC. | $566.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $437.92 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $404.70 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Celgene Corporation | $398.43 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $347.24 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $299.40 | 2019-2022 | |
| Daiichi Sankyo INC. | $277.86 | 2019-2025 | Enhertu, Datroway |
| Abbvie INC. | $214.78 | 2019-2025 | |
| Eisai INC. | $208.96 | 2019-2025 | |
| Puma Biotechnology, INC. | $143.52 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.22 | 2019-2023 | |
| Octapharma USA, INC. | $137.89 | 2019 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $132.11 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Gilead Sciences, INC. | $131.69 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $105.64 | 2024-2025 | Vyloy, Xtandi, Padcev |
| Exelixis INC. | $99.05 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $94.74 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Alexion Pharmaceuticals, INC. | $89.36 | 2019-2024 | Ultomiris |
| Mirati Therapeutics, INC. | $88.27 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $88.20 | 2019-2025 | Tavalisse, Rezlidhia, Gavreto |
| Takeda Pharmaceuticals U.S.A., INC. | $81.28 | 2024-2025 | Iclusig, Alunbrig, Fruzaqla |
| Aveo Pharmaceuticals, INC. | $80.04 | 2022-2025 | |
| Genentech USA, INC. | $74.15 | 2019-2025 | Polivy |
| Ge Healthcare | $67.43 | 2021 | |
| Genzyme Corporation | $65.12 | 2025 | |
| Jazz Pharmaceuticals INC. | $61.51 | 2024-2025 | |
| Stemline Therapeutics INC. | $52.10 | 2024-2025 | Orserdu |
| Sobi, INC | $47.85 | 2024-2025 | |
| Cti Biopharma Corp. | $43.07 | 2022-2023 | Vonjo |
| Emmaus Medical, INC. | $36.84 | 2019-2024 | Endari |
| Pharmaessentia USA Corporation | $36.52 | 2024 | Besremi |
| Azurity Pharmaceuticals, INC. | $33.81 | 2025 | Danziten |
| Blueprint Medicines Corporation | $31.86 | 2023-2024 | Ayvakit |
| Array Biopharma INC | $31.28 | 2022-2025 | Braftovi, Tukysa, Mektovi |
| Dendreon Pharmaceuticals LLC | $30.95 | 2025 | Provenge |
| Beone Medicines USA, INC. | $29.36 | 2025 | Tevimbra |
| Genmab U.S., INC. | $26.05 | 2025 | Tivdak |
| Karyopharm Therapeutics INC. | $20.88 | 2024 | Xpovio |
| Spectrum Pharmaceuticals INC. | $20.07 | 2023 | Rolvedon |
| Adaptive Biotechnologies Corporation | $19.51 | 2025 | Clonoseq |
| Agios Pharmaceuticals, INC. | $17.48 | 2023 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $16.39 | 2023 | Monoferric |
| Exact Sciences Corporation | $15.99 | 2025 | Cologuard Collection Kit |
| Regeneron Healthcare Solutions, INC. | $15.48 | 2024 | Libtayo |
| Galvanize Therapeutics, INC | $14.99 | 2025 | Aliya System |
| Morphosys, US INC. | $14.99 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $14.98 | 2020 | |
| Novocure INC. | $14.90 | 2025 | Optune Lua (Novottf-200t) |
| Advanced Accelerator Applications | $14.83 | 2020 | |
| Global Blood Therapeutics, INC. | $14.17 | 2021 | |
| Glaxosmithkline, LLC. | $13.91 | 2025 | Ojjaara |
| Dova Pharmaceuticals | $11.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richards Afonja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.